DNA Diagnostics Market Size, Industry Share & Trends | 2031
DNA Diagnostics Market Size, Industry Share & Trends | 2031
Segments - DNA Diagnostics Market by Type (PCR-based Diagnostics, In situ hybridization Diagnostics, Fluorescence in situ hybridization, Next-Generation Sequencing DNA Diagnosis, Microarrays, and Others), Product (Instruments, Reagents, and Services & Software), Application (Oncology, Infectious Diseases, Genetic Disorders, Others), End-user (Hospitals, Research Institutes, Diagnostic Centers, and Others), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-5477
| 4.8 Rating
| 65 Reviews
| 189 Pages
| Format :
Report Description
The global DNA diagnostics market size was USD 22.7 Billion in 2022 and is likely to reach USD 51.5 Billion by 2031, expanding at a CAGR of 9.5% during 2023–2031. The market is driven by the increasing demand for personalized medicine & treatments and the possibility of early detection of chronic diseases through DNA diagnostic methods.
The DNA diagnostics demand is driven by its growing integration with medical diagnostics procedures. It assists healthcare experts to identify different health conditions associated with the person’s DNA.
Chronic conditions such as infectious diseases, myogenic disorders, and different cancer types are anticipated to have an increasing number of incidences in the coming years, owing to unhealthy eating habits and sedentary lifestyles. However, they can be discovered and treated with the help of DNA diagnostic technology, which is further expected to provide major expansion scope for the market. For instance,
-
According to a report by the National Institutes of Health, it is estimated that by 2030, the number of novel cancer cases in the US is expected to reach around 26 million. The report also stated that over 17 million deaths due to cancer are estimated to occur by 2030. These factors further propel the demand for DNA diagnostic solutions.
The advancements in product designs of DNA diagnostics equipment, help doctors and healthcare experts in carrying out the diagnosis easily and with high accuracy. This is likely to drive the adoption of updated DNA disease diagnostic methods as compared to conventional diagnostic methods.
Such growing implementation of advanced diagnostics techniques that provide improvements over existing diagnostics and treatment technology, is anticipated to generate growth opportunities for the market players.
The market report finds that the COVID-19 pandemic propelled the growth of the DNA diagnostics market, as there was an upsurge in the utilization of diagnostics technology for developing treatments and drugs associated with the coronavirus disease.
Some of the diagnostic coronavirus tests include molecular tests such as nucleic acid amplification tests (NAATs) and polymerase chain reaction (PCR). These tests detect the genetic material (RNA) from the virus. Thus, such diagnostic solutions were highly implemented during the COVID-19 pandemic, for the detection of the virus and treatment of patients, fueling the growth of the market.
DNA Diagnostics Market Dynamics
Major Drivers
Increasing prevalence of different cancer types worldwide is projected to propel the market. According to updated information published on the NIH Nation Cancer Institute portal, in March 2023, the most commonly occurring cancer in the US is breast cancer (300, 590 cases expected in 2023).
It is followed by prostate cancer, lung cancer, and colorectal cancer. DNA diagnostics help in anticipating one’s chance to develop cancer during the lifetime, which helps in early diagnostics and preventive measures.
The wide range of applications of DNA diagnostics solutions such as clinical confirmation and prenatal diagnostics are boosting the market. The rise in product innovations and designs has increased doctors’ usage of DNA diagnostics, owing to a preference for advanced technologies over traditional methods. The increasing trends in genetic testing for health determination and managing various stages of disease development are anticipated to further market growth.
Existing Restraints
Lack of awareness about DNA diagnostic methods and stringent government regulations are expected to affect the market growth. The high cost of diagnostic reagents & services and the presence of cheaper alternatives is expected to further impede market growth. Additionally, the shortage of appropriate infrastructure, capital, and skilled experts is further projected to restrain the market during the forecast period.
Emerging Opportunities
Growing research and development activities, supported by a boost in investments for improving DNA diagnostics techniques and platforms, are projected to create growth opportunities for the market. The R&D approach for the development of personalized medicines and treatments is expected to gain considerable significance in the coming years.
Optimization in genome sequencing tools used to decode various human diseases, such as cancer, is expected to support market growth, as it reduces the cost of conventional sequencing methods without compromising efficacy.
Moreover, surging healthcare concerns among different countries across the globe have led various governments to take initiatives on making progress in DNA diagnostics and treatments, which is expected to generate lucrative opportunities in the market.
Scope of DNA Diagnostics Market Report
The report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
DNA Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Type (PCR-based Diagnostics, In situ hybridization Diagnostics, Fluorescence in situ hybridization, Next-Generation Sequencing DNA Diagnosis, Microarrays, and Others), Product (Instruments, Reagents, and Services & Software), Application (Oncology, Infectious Diseases, Genetic Disorders, Others), and End-user (Hospitals, Research Institutes, Diagnostic Centers, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Sysmex Corporation; GE HealthCare; Sansure Biotech Inc.; Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Cepheid; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; QIAGEN; and Abbott |
DNA Diagnostics Market Segment Insights
Type Segment Analysis
On the basis of type, the DNA diagnostics market is segmented into PCR-based diagnostics (polymerase chain reaction), in situ hybridization (ISH) diagnostics, fluorescence in situ hybridization (FISH), next-generation sequencing (NGS) DNA diagnosis, microarrays, and others.
The PCR-based diagnostics segment is expected to register a robust growth rate during the projection period, as it is majorly applied in molecular biology of genetic disorder diagnosis and determining other infections and diseases. This method offers instant, high specificity, and sensitivity. It allows the detection of minor differences in the genes, which help in the growth of the segment.
The ISH diagnostics segment is expected to hold a significant share of the market. It consists of test sets used to identify genetic conditions and analyze the DNA. These tests allow to look at cytosine, methylation, and guanine, in specific regions of the genome called CpG islands. This process helps in detecting changes regarding diabetes or cancer. As the prevalence of such chronic disease is growing it is expected to further drive the segment in the market.
Product Segment Analysis
Based on product, the DNA diagnostics market is trifurcated into instruments, reagents, and services & software. The instruments segment is expected to expand at a significant growth rate during the projection period, owing to the emergence of user-friendly equipment, that enables further improvements in the healthcare industry.
These advanced instruments have a competitive pricing structure, with reliable features and sizes. Additionally, the integration of innovative technology in the field of testing equipment is anticipated to drive the segment.
The services & software segment is anticipated to account for a major market share during the forecast period, due to the growing implementation of information technology in diagnostic systems.
The adoption of innovative solutions such as cloud-based applications and desktop software, helps in the effective discovery and diagnostics of disorders related to DNA. In addition, DNA software help in reducing the discovery timeline from months to a few minutes, which in turn propels the segment.
Application Segment Analysis
On the basis of application, the market is segregated into oncology, infectious diseases, genetic disorders, preimplantation diagnostics, prenatal diagnostics, and others. The oncology segment is projected to register a considerable CAGR during the forecast period, due to the rising incidence of cancer cases across population in various age groups, especially the geriatric population.
Prostate cancer, colorectal cancer, and breast cancer are some of the major cancer types prevailing among people. Thus, to address this, DNA diagnostics are used, which is further boosting the market segment. The prenatal diagnostics segment accounts for a significant market share, due to the expected rise in the demand for prenatal screening for the detection of congenital abnormalities in newborns.
As medical research and detection help doctors in making better decisions for treatment, DNA diagnostics help in prenatal diagnostics to discover and treat chromosomal abnormalities, which drives the segment.
End-user Segment Analysis
Based on end-user, the DNA diagnostics market is divided into hospitals, research institutes, diagnostic centers, and others. The hospitals segment is expected to expand at a significant growth rate during the projection period, as there are increasing genetic and cancer cases across the world, that need hospitalization.
Additionally, the rising popularity of assisted reproductive technology is causing a surge in cases of chromosomal abnormalities in newborns, which further drives the need for DNA diagnosis in hospitals. The diagnostic centers segment is anticipated to account for a significant market share during the forecast period, as they help in discovering the early stages of different gene-related diseases.
Diagnostic centers are equipped with modern technology solutions that assist doctors to instantly examine the drug effect and changes in the patient, for a personalized and effective treatment. These centers have specific equipment required for DNA diagnosis, which is further likely to propel the segment.
Regional Analysis
In terms of region, the global DNA diagnostics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the forecast period, as there is a rising prevalence of infections and chronic diseases in the region. In addition, the increasing popularity of DNA diagnostics technology and the presence of major players in North America is likely to further drive the regional market.
-
According to the latest information from the Centers for Disease Control and Prevention (CDC), around 51% of adults in the US are anticipated to have at least one chronic disease, whereas about 27% of people had more than one chronic disease.
The market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period, due to the expanding healthcare infrastructure in emerging economies such as India and China. In addition, the increasing prevalence of chronic conditions is expected to drive the demand for DNA diagnostics. The rising investment activities in R&D for different diagnostic systems, are further projected to boost the market.
Segments
The DNA diagnostics market has been segmented on the basis of
Type
- PCR-based Diagnostics
- In situ hybridization (ISH) Diagnostics
- Fluorescence in situ hybridization (FISH)
- Next-Generation Sequencing (NGS) DNA Diagnosis
- Microarrays
- Others
Product
- Instruments
- Reagents
- Services & Software
Application
- Oncology
- Infectious Diseases
- Genetic Disorders
- Others
End-User
- Hospitals
- Research Institutes
- Diagnostic Centers
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Sysmex Corporation
- GE HealthCare
- Sansure Biotech Inc.
- Bio-Rad Laboratories, Inc.
- Siemens Healthcare GmbH
- Cepheid
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- QIAGEN
- Abbott
Competitive Landscape
Key players operating in the global DNA diagnostics market include Sysmex Corporation; GE HealthCare; Sansure Biotech Inc.; Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Cepheid; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; QIAGEN; and Abbott
These companies adopt growth strategies such as acquisitions, partnerships, collaboration, mergers, R&D investments, and product launches to boost their market share. For instance,
-
In February 2022, Sysmex Corporation, a healthcare business firm based in Japan, announced its partnership with KAINOS Laboratories, Inc. in terms of business and capital, to strengthen the production and development of diagnostic reagents for the immunochemistry sector.
-
On 6 January 2022,Sansure Biotech Inc.’s HPV DNA Diagnostic Kit received approval from China NMPA. This product helps promote the elimination of cervical cancer across the globe.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. DNA Diagnostics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. DNA Diagnostics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. DNA Diagnostics Market - Supply Chain
4.5. Global DNA Diagnostics Market Forecast
4.5.1. DNA Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. DNA Diagnostics Market Size (000’ Units) and Y-o-Y Growth
4.5.3. DNA Diagnostics Market Absolute $ Opportunity
5. Global DNA Diagnostics Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. DNA Diagnostics Market Size and Volume Forecast by Types
5.3.1. PCR-based Diagnostics
5.3.2. In situ hybridization (ISH) Diagnostics
5.3.3. Fluorescence in situ hybridization (FISH)
5.3.4. Next-Generation Sequencing (NGS) DNA Diagnosis
5.3.5. Microarrays
5.3.6. Others
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global DNA Diagnostics Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. DNA Diagnostics Market Size and Volume Forecast by Applications
6.3.1. Oncology
6.3.2. Infectious Diseases
6.3.3. Genetic Disorders
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global DNA Diagnostics Market Analysis and Forecast by End Users
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by End Users
7.2.2. Y-o-Y Growth Projections by End Users
7.3. DNA Diagnostics Market Size and Volume Forecast by End Users
7.3.1. Hospitals
7.3.2. Research Institutes
7.3.3. Diagnostic Centers
7.3.4. Others
7.4. Absolute $ Opportunity Assessment by End Users
7.5. Market Attractiveness/Growth Potential Analysis by End Users
8. Global DNA Diagnostics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. DNA Diagnostics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global DNA Diagnostics Demand Share Forecast, 2019-2026
9. North America DNA Diagnostics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America DNA Diagnostics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America DNA Diagnostics Market Size and Volume Forecast by Types
9.4.1. PCR-based Diagnostics
9.4.2. In situ hybridization (ISH) Diagnostics
9.4.3. Fluorescence in situ hybridization (FISH)
9.4.4. Next-Generation Sequencing (NGS) DNA Diagnosis
9.4.5. Microarrays
9.4.6. Others
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. North America DNA Diagnostics Market Size and Volume Forecast by Applications
9.7.1. Oncology
9.7.2. Infectious Diseases
9.7.3. Genetic Disorders
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. North America DNA Diagnostics Market Size and Volume Forecast by End Users
9.10.1. Hospitals
9.10.2. Research Institutes
9.10.3. Diagnostic Centers
9.10.4. Others
9.11. Basis Point Share (BPS) Analysis by End Users
9.12. Y-o-Y Growth Projections by End Users
9.13. Market Attractiveness/Growth Potential Analysis
9.13.1. By Country
9.13.2. By Product Type
9.13.3. By Application
9.14. North America DNA Diagnostics Demand Share Forecast, 2019-2026
10. Latin America DNA Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America DNA Diagnostics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America DNA Diagnostics Market Size and Volume Forecast by Types
10.4.1. PCR-based Diagnostics
10.4.2. In situ hybridization (ISH) Diagnostics
10.4.3. Fluorescence in situ hybridization (FISH)
10.4.4. Next-Generation Sequencing (NGS) DNA Diagnosis
10.4.5. Microarrays
10.4.6. Others
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Latin America DNA Diagnostics Market Size and Volume Forecast by Applications
10.7.1. Oncology
10.7.2. Infectious Diseases
10.7.3. Genetic Disorders
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Latin America DNA Diagnostics Market Size and Volume Forecast by End Users
10.10.1. Hospitals
10.10.2. Research Institutes
10.10.3. Diagnostic Centers
10.10.4. Others
10.11. Basis Point Share (BPS) Analysis by End Users
10.12. Y-o-Y Growth Projections by End Users
10.13. Market Attractiveness/Growth Potential Analysis
10.13.1. By Country
10.13.2. By Product Type
10.13.3. By Application
10.14. Latin America DNA Diagnostics Demand Share Forecast, 2019-2026
11. Europe DNA Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe DNA Diagnostics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe DNA Diagnostics Market Size and Volume Forecast by Types
11.4.1. PCR-based Diagnostics
11.4.2. In situ hybridization (ISH) Diagnostics
11.4.3. Fluorescence in situ hybridization (FISH)
11.4.4. Next-Generation Sequencing (NGS) DNA Diagnosis
11.4.5. Microarrays
11.4.6. Others
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Europe DNA Diagnostics Market Size and Volume Forecast by Applications
11.7.1. Oncology
11.7.2. Infectious Diseases
11.7.3. Genetic Disorders
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Europe DNA Diagnostics Market Size and Volume Forecast by End Users
11.10.1. Hospitals
11.10.2. Research Institutes
11.10.3. Diagnostic Centers
11.10.4. Others
11.11. Basis Point Share (BPS) Analysis by End Users
11.12. Y-o-Y Growth Projections by End Users
11.13. Market Attractiveness/Growth Potential Analysis
11.13.1. By Country
11.13.2. By Product Type
11.13.3. By Application
11.14. Europe DNA Diagnostics Demand Share Forecast, 2019-2026
12. Asia Pacific DNA Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific DNA Diagnostics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific DNA Diagnostics Market Size and Volume Forecast by Types
12.4.1. PCR-based Diagnostics
12.4.2. In situ hybridization (ISH) Diagnostics
12.4.3. Fluorescence in situ hybridization (FISH)
12.4.4. Next-Generation Sequencing (NGS) DNA Diagnosis
12.4.5. Microarrays
12.4.6. Others
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Asia Pacific DNA Diagnostics Market Size and Volume Forecast by Applications
12.7.1. Oncology
12.7.2. Infectious Diseases
12.7.3. Genetic Disorders
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Asia Pacific DNA Diagnostics Market Size and Volume Forecast by End Users
12.10.1. Hospitals
12.10.2. Research Institutes
12.10.3. Diagnostic Centers
12.10.4. Others
12.11. Basis Point Share (BPS) Analysis by End Users
12.12. Y-o-Y Growth Projections by End Users
12.13. Market Attractiveness/Growth Potential Analysis
12.13.1. By Country
12.13.2. By Product Type
12.13.3. By Application
12.14. Asia Pacific DNA Diagnostics Demand Share Forecast, 2019-2026
13. Middle East & Africa DNA Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Middle East & Africa Average Pricing Analysis
13.2. Middle East & Africa DNA Diagnostics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa DNA Diagnostics Market Size and Volume Forecast by Types
13.4.1. PCR-based Diagnostics
13.4.2. In situ hybridization (ISH) Diagnostics
13.4.3. Fluorescence in situ hybridization (FISH)
13.4.4. Next-Generation Sequencing (NGS) DNA Diagnosis
13.4.5. Microarrays
13.4.6. Others
13.5. Basis Point Share (BPS) Analysis by Types
13.6. Y-o-Y Growth Projections by Types
13.7. Middle East & Africa DNA Diagnostics Market Size and Volume Forecast by Applications
13.7.1. Oncology
13.7.2. Infectious Diseases
13.7.3. Genetic Disorders
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Applications
13.9. Y-o-Y Growth Projections by Applications
13.10. Middle East & Africa DNA Diagnostics Market Size and Volume Forecast by End Users
13.10.1. Hospitals
13.10.2. Research Institutes
13.10.3. Diagnostic Centers
13.10.4. Others
13.11. Basis Point Share (BPS) Analysis by End Users
13.12. Y-o-Y Growth Projections by End Users
13.13. Market Attractiveness/Growth Potential Analysis
13.13.1. By Country
13.13.2. By Product Type
13.13.3. By Application
13.14. Middle East & Africa DNA Diagnostics Demand Share Forecast, 2019-2026
14. Competition Landscape
14.1. Global DNA Diagnostics Market: Market Share Analysis
14.2. DNA Diagnostics Distributors and Customers
14.3. DNA Diagnostics Market: Competitive Dashboard
14.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
14.4.1. Sysmex Corporation
14.4.2. GE HealthCare
14.4.3. Sansure Biotech Inc.
14.4.4. Bio-Rad Laboratories, Inc.
14.4.5. Siemens Healthcare GmbH
14.4.6. Cepheid
14.4.7. F. Hoffmann-La Roche Ltd
14.4.8. Thermo Fisher Scientific Inc.
14.4.9. QIAGEN
14.4.10. Abbott
Methodology
Related Reports
Some other reports from this category!
Our Clients
